Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study


The demonstration of the link between certain genetic variations and drug response has allowed the emergence of pharmacogenetics, which offers many opportunities to improve patient care. Type-2 diabetes mellitus is a disease for which several gene polymorphisms have been reported to be associated with drug response. Sulfonylureas are commonly used for the management of this disease. Genetic polymorphisms of CYP2C9, the main enzyme involved in the metabolism of sulfonylureas, have been associated with the risk of severe hypoglycaemia, particularly in poor metabolizers carrying CYP2C9 *3/*3 genotype, and especially in the case of patients treated with glimepiride. The objectives of the present study were to evaluate the potential clinical and economic outcomes of using CYP2C9 genotype data to guide the management of SU regimen in patients initiating glimepiride therapy, and to identify factors affecting the cost-effectiveness of this treatment scheme. The analysis was conducted using a decision tree, considering a 1-year time horizon, and taking as perspective that of the French national health insurance system. With pharmacogenetic-guided therapy, the cost to avoid an episode of severe hypoglycaemia event per 100 000 patients treated was €421 834. Genotyping cost was the most influential factor on the incremental cost-effectiveness ratio. In conclusion, the potential cost of CYP2C9 genotype-guided dosing for glimepiride therapy is relatively high, and associated with modest improvements with respect to the number of hypoglycaemia avoided, as compared with standard dosing. Additional economic studies are required to better specify the usefulness of CYP2C9 genotyping prior to glimepiride regimen initiation.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2


  1. 1.

    Allorge D, Loriot M-A. La pharmacogénétique ou la promesse d’une médecine personnalisée: variations du métabolisme et du transport des médicaments. Ann Biol Clin (Paris). 2004;62:499–511.

    CAS  Google Scholar 

  2. 2.

    Charbonnel B, Simon D, Dallongeville J, Bureau I, Gourmelen J, Detournay B. Coût du diabète de type 2 en France: une analyse des données de l’EGB. Médecine Mal Métaboliques. 2017;11:IIS24–7.

    Article  Google Scholar 

  3. 3.

    Inserm. Diabète de type 2. 2014. Accessed April 11, 2018.

  4. 4.

    Piffaretti C, Fagot-Campagna A, Rey G, Antero-Jacquemin J, Latouche A, Mandereau-Bruno L, et al. Déterminants de la mortalité des personnes diabétiques de type 2. Cohortes Entred, France, 2002–2013;2016.

  5. 5.

    Halimi S. Hypoglycémie 2002. Accessed April 11, 2018.

  6. 6.

    Cariou B, Fontaine P, Eschwege E, Lièvre M, Gouet D, Huet D, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41:116–25.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Sultan A. Hypoglycémie et risque cardiovasculaire dans le diabète de type 1 et de type 2. Médecine Mal Métaboliques. 2016;10:13–4.

    Article  Google Scholar 

  8. 8.

    Grimaldi A, Slama G, Tubiana-Rufi N, Heurtier A, Selam JL, Scheen A, et al. L’hypoglycémie du patient diabétique. Diabetes Metab. 1997;23:100–8.

    CAS  PubMed  Google Scholar 

  9. 9.

    Harris S, Mamdani M, Galbo-Jørgensen CB, Bøgelund M, Gundgaard J, Groleau D. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes. 2014;38:45–52.

    Article  PubMed  Google Scholar 

  10. 10.

    Detournay B, Halimi S, Torreton E, Levy P. Coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2: étude fondée sur le PMSI et la base EGB de la CNAMTS. Médecine Mal Métaboliques. 2017;11:IIS16–9.

    Article  Google Scholar 

  11. 11.

    Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010;8:359–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Glasser L, Alt-Tebacher M, Schlienger J-L. Hypoglycémies iatrogènes: Iatrogenic hypoglycemias. Médecine Mal Métaboliques. 2011;5:377–81.

    Article  Google Scholar 

  13. 13.

    van Leeuwen N, Swen JJ, Guchelaar H-J, ’t Hart LM. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet. 2013;52:833–54.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018;27:9–18.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharm Ther. 2014;95:199–207.

    CAS  Article  Google Scholar 

  16. 16.

    You JHS, Chan FWH, Wong RSM, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb Haemost. 2004;92:590–7.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharm Ther. 2004;20:593–9.

    CAS  Article  Google Scholar 

  18. 18.

    Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17:22–33.

    Article  PubMed  Google Scholar 

  19. 19.

    Butzke B, Oduncu FS, Severin F, Pfeufer A, Heinemann V, Giessen-Jung C, et al. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. Acta Oncol. 2016;55:318–28.

    Article  PubMed  Google Scholar 

  20. 20.

    Pichereau S, Le Louarn A, Lecomte T, Blasco H, Le Guellec C, Bourgoin H. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. J Pharm Pharm Sci. 2010;13:615–25.

    Article  Google Scholar 

  21. 21.

    Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, et al. Cost evaluation of irinotecan-related toxicities associated with the UGT1A1*28 patient genotype. Clin Pharm Ther. 2017;102:123–30.

    CAS  Article  Google Scholar 

  22. 22.

    Deiman BALM, Tonino PAL, Kouhestani K, Schrover CEM, Scharnhorst V, Dekker LRC, et al. Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J. 2016;24:589–99.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Mitropoulou C, Fragoulakis V, Rakicevic LB, Novkovic MM, Vozikis A, Matic DM, et al. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics. 2016.

    Article  PubMed  Google Scholar 

  24. 24.

    Herbild L, Bech M, Gyrd-Hansen D, Christensen M, Werge T, Nielsen KA. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services? Scand J Public Health. 2011;39:147–55.

    Article  PubMed  Google Scholar 

  25. 25.

    Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharm Toxicol. 2013;113:266–72.

    CAS  Article  Google Scholar 

  26. 26.

    Martin MA, Kroetz DL. Abacavir pharmacogenetics – from initial reports to standard of care. Pharmacotherapy. 2013;33:765–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Allorge D, Beaune P-H, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, et al. La pharmacogénétique moléculaire hospitalière en France: données actuelles et perspectives. Ann Pharm Fr. 2007;65:371–81.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Haute Autorité de Santé. Stratégie médicamenteuse du contrôle glycémique du diabète de type 2. 2013.

  29. 29.

    Faure S. Sulfamides hypoglycémiants. Actual Pharm. 2011;50:53–6.

    Article  Google Scholar 

  30. 30.

    Darmon P, Bauduceau B, Bordier L, Bringer J, Chabrier G, Charbonnel B, et al. Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l’hyperglycémie du patient diabétique de type 2. Médecine Mal Métaboliques. 2017;11:577–93.

    Article  Google Scholar 

  31. 31.

    Wiley LK, Vanhouten JP, Samuels DC, Aldrich MC, Roden DM, Peterson JF, et al. Strategies for equitable pharmacogenomic-guided warfarin dosing among European and African American individuals in a clinical population. Pac Symp Biocomput. 2017;22:545–56.

    Article  PubMed  Google Scholar 

  32. 32.

    Li X, Liu R, Yan H, Tang J, Yin J-Y, Mao X-Y, et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J Clin Pharm. 2015;55:251–7.

    CAS  Article  Google Scholar 

  33. 33.

    Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254:628–31.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharm. 2011;67:471–6.

    CAS  Article  Google Scholar 

  35. 35.

    Schloot NC, Haupt A, Schütt M, Badenhoop K, Laimer M, Nicolay C, et al. Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: how big is the problem? Which patients are at risk? Diabetes Metab Res Rev. 2016;32:316–24.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag. 2015;11:417–25.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The authors thank Dr. Myriam Moret and Dr. Michel Bensimon for help in the obtention of the clinical parameters of the study. The authors also thank Philip Robinson and Verena Landel (DRCI, Hospices Civils de Lyon) for help in manuscript preparation.

Author information



Corresponding author

Correspondence to Cécile Fokoun.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fokoun, C., Serrier, H., Rabier, H. et al. Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. Pharmacogenomics J 21, 559–565 (2021).

Download citation


Quick links